You just read:

Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Jul 01, 2019, 07:30 ET